Skip to main content
Top
Published in: Drugs 7/2008

01-05-2008 | Review Article

Renal Disease in Patients with HIV Infection

Epidemiology, Pathogenesis and Management

Authors: Dr Derek M. Fine, Mark A. Perazella, Gregory M. Lucas, Mohamed G. Atta

Published in: Drugs | Issue 7/2008

Login to get access

Abstract

With the introduction of highly active antiretroviral therapy, we have witnessed prolonged survival with the potential for normal life expectancy in HIV-infected individuals. With improved survival and increasing age, HIV-infected patients are increasingly likely to experience co-morbidities that affect the general population, including kidney disease. Although HIV-associated nephropathy, the most ominous kidney disease related to the direct effects of HIV, may be prevented and treated with antiretrovirals, kidney disease remains an important issue in this population. In addition to the common risk factors for kidney disease of diabetes mellitus and hypertension, HIV-infected individuals have a high prevalence of other risk factors, including hepatitis C, cigarette smoking and injection drug use. Furthermore, they have exposures unique to this population, including antiretrovirais and other medications. Therefore, the differential diagnosis is vast.
Early identification (through efficient screening) and definitive diagnosis (by kidney biopsy when indicated) of kidney disease in HIV-infected individuals are critical to optimal management. Earlier interventions with disease-specific therapy, often with the help of a nephrologist, are likely to lead to better outcomes. In those with chronic kidney disease, interventions, such as aggressive blood pressure control with the use of ACE inhibitors or angiotensin receptor antagonists where tolerated, tight blood glucose control in those with diabetes, and avoidance of potentially nephrotoxic medications, can slow progression and prevent end-stage renal disease. Only with greater awareness of kidney-disease manifestations and their implications in this particularly vulnerable population will we be able to achieve success in confronting this growing problem.
Literature
2.
go back to reference Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007 Feb 1; 44(2): 179–87PubMedCrossRef Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007 Feb 1; 44(2): 179–87PubMedCrossRef
3.
go back to reference Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006 Oct; 21(10): 2809–13PubMedCrossRef Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006 Oct; 21(10): 2809–13PubMedCrossRef
4.
go back to reference Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004 Feb 20; 18(3): 541–6PubMedCrossRef Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004 Feb 20; 18(3): 541–6PubMedCrossRef
5.
go back to reference Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984 Oct; 101(4): 429–34PubMed Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984 Oct; 101(4): 429–34PubMed
6.
go back to reference Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984 Mar 15; 310(11): 669–73PubMedCrossRef Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984 Mar 15; 310(11): 669–73PubMedCrossRef
7.
go back to reference Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002 Dec; 13(12): 2997–3004PubMedCrossRef Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002 Dec; 13(12): 2997–3004PubMedCrossRef
8.
go back to reference Selik RM, Byers Jr RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002 Apr 1; 29(4): 378–87 Selik RM, Byers Jr RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002 Apr 1; 29(4): 378–87
9.
go back to reference Franceschini N, Napravnik S, Eron Jr JJ, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005 Apr; 67(4): 1526–31PubMedCrossRef Franceschini N, Napravnik S, Eron Jr JJ, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005 Apr; 67(4): 1526–31PubMedCrossRef
10.
go back to reference Wyatt CM, Arons RR, Klotman PE, et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on inhospital mortality. AIDS 2006 Feb 28; 20(4): 561–5PubMedCrossRef Wyatt CM, Arons RR, Klotman PE, et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on inhospital mortality. AIDS 2006 Feb 28; 20(4): 561–5PubMedCrossRef
11.
go back to reference Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006 Aug 1; 43(3): 377–80PubMedCrossRef Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006 Aug 1; 43(3): 377–80PubMedCrossRef
12.
go back to reference Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007 Nov 30; 21(18): 2435–43PubMedCrossRef Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007 Nov 30; 21(18): 2435–43PubMedCrossRef
16.
go back to reference Centers for Disease Control and Prevention (CDC). Racial/ ethnic disparities in prevalence, treatment, and control of hypertension: United States, 1999–2002. MMWR Morb Mortal Wkly Rep 2005; 54(1): 7–9 Centers for Disease Control and Prevention (CDC). Racial/ ethnic disparities in prevalence, treatment, and control of hypertension: United States, 1999–2002. MMWR Morb Mortal Wkly Rep 2005; 54(1): 7–9
17.
go back to reference Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007 Nov; 18(11): 2968–74PubMedCrossRef Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007 Nov; 18(11): 2968–74PubMedCrossRef
18.
go back to reference Choi AI, Rodriguez RA, Bacchetti P, et al. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007 Dec; 72(11): 1380–7PubMedCrossRef Choi AI, Rodriguez RA, Bacchetti P, et al. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007 Dec; 72(11): 1380–7PubMedCrossRef
19.
go back to reference Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007 Oct 1; 21(15): 2101–3PubMedCrossRef Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007 Oct 1; 21(15): 2101–3PubMedCrossRef
20.
go back to reference Atta MG, Fine DM, Kirk GD, et al. Survival on renal replacement therapy among African Americans infected with HIV-1 in urban Baltimore. Clin Infect Dis 2007; 45(12): 1625–32PubMedCrossRef Atta MG, Fine DM, Kirk GD, et al. Survival on renal replacement therapy among African Americans infected with HIV-1 in urban Baltimore. Clin Infect Dis 2007; 45(12): 1625–32PubMedCrossRef
21.
go back to reference Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 Jun 1; 40(11): 1559–85PubMedCrossRef Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 Jun 1; 40(11): 1559–85PubMedCrossRef
22.
go back to reference Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004 Feb 18; 291(7): 844–50PubMedCrossRef Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004 Feb 18; 291(7): 844–50PubMedCrossRef
23.
go back to reference Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006 Jul; 1(4): 655–67PubMedCrossRef Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006 Jul; 1(4): 655–67PubMedCrossRef
24.
go back to reference Orth SR, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant 2000 Oct; 15(10): 1509–11PubMedCrossRef Orth SR, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant 2000 Oct; 15(10): 1509–11PubMedCrossRef
25.
go back to reference Fine DM, Garg N, Haas M, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol 2007 Nov; 2(6): 1125–30PubMedCrossRef Fine DM, Garg N, Haas M, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol 2007 Nov; 2(6): 1125–30PubMedCrossRef
26.
go back to reference Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988; 39: 465–90PubMedCrossRef Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988; 39: 465–90PubMedCrossRef
27.
go back to reference Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985 Nov; 28(5): 830–8PubMedCrossRef Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985 Nov; 28(5): 830–8PubMedCrossRef
28.
go back to reference Johnson RJ, Feehally J. Comprehensive clinical nephrology. 2nd ed. St Louis (MO): Mosby, 2000: 2–33 Johnson RJ, Feehally J. Comprehensive clinical nephrology. 2nd ed. St Louis (MO): Mosby, 2000: 2–33
29.
go back to reference Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006 Jun 8; 354(23): 2473–83PubMedCrossRef Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006 Jun 8; 354(23): 2473–83PubMedCrossRef
30.
go back to reference Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007 Nov 12; 167(20): 2213–9PubMedCrossRef Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007 Nov 12; 167(20): 2213–9PubMedCrossRef
32.
go back to reference Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005 Aug 16; 112(7): 969–75PubMedCrossRef Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005 Aug 16; 112(7): 969–75PubMedCrossRef
33.
go back to reference Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 Oct 1; 106(14): 1777–82PubMedCrossRef Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 Oct 1; 106(14): 1777–82PubMedCrossRef
34.
go back to reference Szczech LA, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS 2007 May 11; 21(8): 1003–9PubMedCrossRef Szczech LA, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS 2007 May 11; 21(8): 1003–9PubMedCrossRef
35.
go back to reference Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003 Nov 1; 34(3): 320–30PubMedCrossRef Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003 Nov 1; 34(3): 320–30PubMedCrossRef
36.
go back to reference Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004 Oct 15; 39(8): 1199–206PubMedCrossRef Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004 Oct 15; 39(8): 1199–206PubMedCrossRef
37.
go back to reference Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983 Dec 22; 309(25): 1543–6PubMedCrossRef Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983 Dec 22; 309(25): 1543–6PubMedCrossRef
39.
go back to reference Siedner MJ, Atta MG, Lucas GM, et al. Poor Validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndr 2008 Feb 1; 47(2): 261–3PubMedCrossRef Siedner MJ, Atta MG, Lucas GM, et al. Poor Validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndr 2008 Feb 1; 47(2): 261–3PubMedCrossRef
40.
go back to reference Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002 May; 39(5): 930–6PubMedCrossRef Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002 May; 39(5): 930–6PubMedCrossRef
41.
go back to reference Cheng JT, Anderson Jr HL, Markowitz GS, et al. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999 Jul; 10(7): 1566–74PubMed Cheng JT, Anderson Jr HL, Markowitz GS, et al. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999 Jul; 10(7): 1566–74PubMed
42.
go back to reference Fine DM, Gelber AC, Melamed ML, et al. Risk factors for renal failure among 72 consecutive patients with rhabdomyolysis related to illicit drug use. Am J Med 2004 Oct 15; 117(8): 607–10PubMedCrossRef Fine DM, Gelber AC, Melamed ML, et al. Risk factors for renal failure among 72 consecutive patients with rhabdomyolysis related to illicit drug use. Am J Med 2004 Oct 15; 117(8): 607–10PubMedCrossRef
43.
go back to reference Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002 May; 1(1): 5–17PubMedCrossRef Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002 May; 1(1): 5–17PubMedCrossRef
44.
go back to reference Rastegar D, Claiborne C, Fleisher A, et al. A patient with primary human immunodeficiency virus infection who presented with acute rhabdomyolysis. Clin Infect Dis 2001 Feb 1; 32(3): 502–4PubMedCrossRef Rastegar D, Claiborne C, Fleisher A, et al. A patient with primary human immunodeficiency virus infection who presented with acute rhabdomyolysis. Clin Infect Dis 2001 Feb 1; 32(3): 502–4PubMedCrossRef
45.
go back to reference Winston JA, Klotman PE. Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 1996 Jan; 7(1): 1–7PubMed Winston JA, Klotman PE. Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 1996 Jan; 7(1): 1–7PubMed
46.
go back to reference Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993; 8(1): 11–9PubMed Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993; 8(1): 11–9PubMed
47.
go back to reference Monahan M, Tanji N, Klotman PE. HIV-associated nephropathy: an urban epidemic. Semin Nephrol 2001 Jul; 21(4): 394–402PubMedCrossRef Monahan M, Tanji N, Klotman PE. HIV-associated nephropathy: an urban epidemic. Semin Nephrol 2001 Jul; 21(4): 394–402PubMedCrossRef
48.
go back to reference D’Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol 1997 Jan; 8(1): 138–52PubMed D’Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol 1997 Jan; 8(1): 138–52PubMed
49.
go back to reference Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987 Apr 23; 316(17): 1062–8PubMedCrossRef Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987 Apr 23; 316(17): 1062–8PubMedCrossRef
50.
go back to reference Ahuja TS, Borucki M, Funtanilla M, et al. Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol 1999; 19(6): 655–9PubMedCrossRef Ahuja TS, Borucki M, Funtanilla M, et al. Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol 1999; 19(6): 655–9PubMedCrossRef
51.
go back to reference Pardo V, Meneses R, Ossa L, et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int 1987 May; 31(5): 1167–73PubMedCrossRef Pardo V, Meneses R, Ossa L, et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int 1987 May; 31(5): 1167–73PubMedCrossRef
52.
go back to reference Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005 Nov; 118(11): 1288.e21-6PubMedCrossRef Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005 Nov; 118(11): 1288.e21-6PubMedCrossRef
53.
go back to reference Han TM, Naicker S, Ramdial PK, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006 Jun; 69(12): 2243–50PubMedCrossRef Han TM, Naicker S, Ramdial PK, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006 Jun; 69(12): 2243–50PubMedCrossRef
54.
go back to reference Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000 Dec; 14(12): 637–45PubMedCrossRef Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000 Dec; 14(12): 637–45PubMedCrossRef
55.
go back to reference Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008 Jan 4; 28(3): 478–86PubMedCrossRef Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008 Jan 4; 28(3): 478–86PubMedCrossRef
56.
go back to reference Atta MG, Longenecker JC, Fine DM, et al. Sonography as a predictor of human immunodeficiency virus-associated nephropathy. J Ultrasound Med 2004 May; 23(5): 603–10PubMed Atta MG, Longenecker JC, Fine DM, et al. Sonography as a predictor of human immunodeficiency virus-associated nephropathy. J Ultrasound Med 2004 May; 23(5): 603–10PubMed
57.
go back to reference Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997 Jul 1; 100(1): 84–92PubMedCrossRef Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997 Jul 1; 100(1): 84–92PubMedCrossRef
58.
go back to reference Ross MJ, Bruggeman LA, Wilson PD, et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001 Dec; 12(12): 2645–51PubMed Ross MJ, Bruggeman LA, Wilson PD, et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001 Dec; 12(12): 2645–51PubMed
59.
go back to reference Barisoni L, Kriz W, Mundel P, et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999 Jan; 10(1): 51–61PubMed Barisoni L, Kriz W, Mundel P, et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999 Jan; 10(1): 51–61PubMed
60.
go back to reference Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001 Jun 28; 344(26): 1979–84PubMedCrossRef Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001 Jun 28; 344(26): 1979–84PubMedCrossRef
62.
go back to reference Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002 Feb; 323(2): 102–6PubMedCrossRef Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002 Feb; 323(2): 102–6PubMedCrossRef
63.
go back to reference Casanova S, Mazzucco G, Barbiano di Belgiojoso G, et al. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 1995 Sep; 26(3): 446–53PubMedCrossRef Casanova S, Mazzucco G, Barbiano di Belgiojoso G, et al. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 1995 Sep; 26(3): 446–53PubMedCrossRef
64.
go back to reference Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney Int 2005 Apr; 67(4): 1381–90PubMedCrossRef Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney Int 2005 Apr; 67(4): 1381–90PubMedCrossRef
65.
go back to reference Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006 May; 69(10): 1885–91PubMedCrossRef Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006 May; 69(10): 1885–91PubMedCrossRef
66.
go back to reference Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992 Sep 3; 327(10): 702–6PubMedCrossRef Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992 Sep 3; 327(10): 702–6PubMedCrossRef
67.
go back to reference Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int 1993 Dec; 44(6): 1327–40PubMedCrossRef Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int 1993 Dec; 44(6): 1327–40PubMedCrossRef
68.
go back to reference Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006 May 15; 42(10): 1488–95PubMedCrossRef Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006 May 15; 42(10): 1488–95PubMedCrossRef
69.
go back to reference Ahmed S, Siddiqui RK, Siddiqui AK, et al. HIV associated thrombotic microangiopathy. Postgrad Med J 2002 Sep; 78(923): 520–5PubMedCrossRef Ahmed S, Siddiqui RK, Siddiqui AK, et al. HIV associated thrombotic microangiopathy. Postgrad Med J 2002 Sep; 78(923): 520–5PubMedCrossRef
70.
go back to reference Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006 Jan; 1(1): 117–29PubMedCrossRef Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006 Jan; 1(1): 117–29PubMedCrossRef
71.
72.
73.
74.
go back to reference Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006 Oct–Dec; 52(4): 296–7PubMed Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006 Oct–Dec; 52(4): 296–7PubMed
75.
go back to reference Krishnan M, Nair R, Haas M, et al. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000 Nov; 36(5): 1075–8PubMedCrossRef Krishnan M, Nair R, Haas M, et al. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000 Nov; 36(5): 1075–8PubMedCrossRef
76.
go back to reference Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005 May 20; 19(8): 844–5PubMedCrossRef Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005 May 20; 19(8): 844–5PubMedCrossRef
77.
go back to reference Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001 Jan 5; 15(1): 140–1PubMedCrossRef Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001 Jan 5; 15(1): 140–1PubMedCrossRef
78.
go back to reference Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 Apr 30; 18(7): 1074–6PubMedCrossRef Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 Apr 30; 18(7): 1074–6PubMedCrossRef
79.
go back to reference Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 Dec; 324(6): 342–4PubMedCrossRef Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 Dec; 324(6): 342–4PubMedCrossRef
80.
go back to reference Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 Apr 15; 36(8): 1070–3PubMedCrossRef Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 Apr 15; 36(8): 1070–3PubMedCrossRef
81.
go back to reference Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004 Aug 15; 117(4): 282–4PubMedCrossRef Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004 Aug 15; 117(4): 282–4PubMedCrossRef
82.
go back to reference Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003 Aug 1; 37(3): e41–3PubMedCrossRef Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003 Aug 1; 37(3): e41–3PubMedCrossRef
83.
go back to reference Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 Dec; 40(6): 1331–3PubMedCrossRef Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 Dec; 40(6): 1331–3PubMedCrossRef
84.
go back to reference Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42(2): 283–90PubMedCrossRef Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42(2): 283–90PubMedCrossRef
85.
go back to reference Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003 Apr 11; 17(6): 935–7PubMedCrossRef Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003 Apr 11; 17(6): 935–7PubMedCrossRef
86.
go back to reference Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008 Feb; 22(2): 99–103PubMedCrossRef Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008 Feb; 22(2): 99–103PubMedCrossRef
87.
go back to reference James CW, Steinhaus MC, Szabo S, et al. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004 Mar; 24(3): 415–8PubMedCrossRef James CW, Steinhaus MC, Szabo S, et al. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004 Mar; 24(3): 415–8PubMedCrossRef
88.
go back to reference Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004 Mar 1; 35(3): 269–73PubMedCrossRef Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004 Mar 1; 35(3): 269–73PubMedCrossRef
89.
go back to reference Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003 Dec 15; 37(12): e174–6PubMedCrossRef Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003 Dec 15; 37(12): e174–6PubMedCrossRef
90.
go back to reference Wirth GJ, Teuscher J, Graf JD, et al. Efavirenz-induced urolithiasis. Urol Res 2006 Aug; 34(4): 288–9PubMedCrossRef Wirth GJ, Teuscher J, Graf JD, et al. Efavirenz-induced urolithiasis. Urol Res 2006 Aug; 34(4): 288–9PubMedCrossRef
91.
92.
93.
go back to reference Pacanowski J, Poirier JM, Petit I, et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006 Oct 24; 20(16): 2131PubMedCrossRef Pacanowski J, Poirier JM, Petit I, et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006 Oct 24; 20(16): 2131PubMedCrossRef
94.
go back to reference Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS 2007 May 31; 21(9): 1215–8PubMedCrossRef Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS 2007 May 31; 21(9): 1215–8PubMedCrossRef
95.
go back to reference Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007 Oct 15; 45(8): e105–8PubMedCrossRef Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007 Oct 15; 45(8): e105–8PubMedCrossRef
96.
go back to reference Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004 Nov; 44(5): e81–4PubMed Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004 Nov; 44(5): e81–4PubMed
97.
go back to reference Cattelan AM, Trevenzoli M, Naso A, et al. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000 Mar; 30(3): 619–21PubMedCrossRef Cattelan AM, Trevenzoli M, Naso A, et al. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000 Mar; 30(3): 619–21PubMedCrossRef
98.
go back to reference Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension. AIDS 2001 Apr 13; 15(6): 805–7PubMedCrossRef Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension. AIDS 2001 Apr 13; 15(6): 805–7PubMedCrossRef
99.
go back to reference Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997 May 3; 349(9061): 1294–5PubMedCrossRef Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997 May 3; 349(9061): 1294–5PubMedCrossRef
100.
go back to reference Dieleman JP, van der Feltz M, Bangma CH, et al. Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection 2001 Aug; 29(4): 232–3PubMedCrossRef Dieleman JP, van der Feltz M, Bangma CH, et al. Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection 2001 Aug; 29(4): 232–3PubMedCrossRef
101.
go back to reference Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000 Sep; 36(3): 507–15PubMedCrossRef Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000 Sep; 36(3): 507–15PubMedCrossRef
102.
go back to reference Jaradat M, Phillips C, Yum MN, et al. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 2000 Apr; 35(4): El 6CrossRef Jaradat M, Phillips C, Yum MN, et al. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 2000 Apr; 35(4): El 6CrossRef
103.
go back to reference Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002 Apr 15; 34(8): 1122–8PubMedCrossRef Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002 Apr 15; 34(8): 1122–8PubMedCrossRef
104.
go back to reference Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997 Jul 15; 127(2): 119–25PubMed Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997 Jul 15; 127(2): 119–25PubMed
105.
106.
go back to reference Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998 Mar; 13(3): 750–3PubMedCrossRef Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998 Mar; 13(3): 750–3PubMedCrossRef
107.
go back to reference Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002 Mar; 167(3): 1384–5PubMedCrossRef Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002 Mar; 167(3): 1384–5PubMedCrossRef
108.
go back to reference Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med 1997 Jan 9; 336(2): 138PubMed Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med 1997 Jan 9; 336(2): 138PubMed
109.
go back to reference Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet 1996 Sep 7; 348(9028): 693PubMedCrossRef Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet 1996 Sep 7; 348(9028): 693PubMedCrossRef
110.
go back to reference Witzke O, Plentz A, Schafers RF, et al. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 1997 May; 11(6): 836–8PubMed Witzke O, Plentz A, Schafers RF, et al. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 1997 May; 11(6): 836–8PubMed
111.
go back to reference Bochet MV, Jacquiaud C, Valantin MA, et al. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998 Nov; 105(5): 457PubMed Bochet MV, Jacquiaud C, Valantin MA, et al. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998 Nov; 105(5): 457PubMed
112.
go back to reference Benveniste O, Longuet P, Duval X, et al. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis 1999 May; 28(5): 1180–1PubMedCrossRef Benveniste O, Longuet P, Duval X, et al. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis 1999 May; 28(5): 1180–1PubMedCrossRef
113.
go back to reference Lalezari JP, Henry K, O’Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003 May 29; 348(22): 2175–85PubMedCrossRef Lalezari JP, Henry K, O’Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003 May 29; 348(22): 2175–85PubMedCrossRef
114.
go back to reference Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978 Nov; 65(5): 756–65PubMedCrossRef Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978 Nov; 65(5): 756–65PubMedCrossRef
115.
go back to reference Buysen JG, Houthoff HJ, Krediet RT, et al. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5(2): 94–9PubMedCrossRef Buysen JG, Houthoff HJ, Krediet RT, et al. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5(2): 94–9PubMedCrossRef
116.
go back to reference Von Bargen J, Moorman A, Holmberg S. How many pills do patients with HIV infection take? JAMA 1998 Jul 1; 280(1): 29CrossRef Von Bargen J, Moorman A, Holmberg S. How many pills do patients with HIV infection take? JAMA 1998 Jul 1; 280(1): 29CrossRef
117.
go back to reference Cruz DN, Perazella MA. Drug-induced acute tubulointerstitial nephritis: the clinical spectrum. Hosp Pract (Minneap) 1998 Feb 15; 33(2): 151–2, 7–8, 61–4 Cruz DN, Perazella MA. Drug-induced acute tubulointerstitial nephritis: the clinical spectrum. Hosp Pract (Minneap) 1998 Feb 15; 33(2): 151–2, 7–8, 61–4
118.
go back to reference Perazella MA. Acute renal failure in HIV-infected patients: a brief review of common causes. Am J Med Sci 2000 Jun; 319(6): 385–91PubMedCrossRef Perazella MA. Acute renal failure in HIV-infected patients: a brief review of common causes. Am J Med Sci 2000 Jun; 319(6): 385–91PubMedCrossRef
119.
go back to reference Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005 Jan; 351(1–2): 31–47PubMedCrossRef Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005 Jan; 351(1–2): 31–47PubMedCrossRef
120.
go back to reference Kopp JB, Klotman ME, Adler SH, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 1992 Mar 1; 89(5): 1577–81PubMedCrossRef Kopp JB, Klotman ME, Adler SH, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 1992 Mar 1; 89(5): 1577–81PubMedCrossRef
121.
go back to reference Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007 Aug; 50(2): 330–5PubMedCrossRef Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007 Aug; 50(2): 330–5PubMedCrossRef
122.
go back to reference Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006 Jan 19; 354(3): 251–60 Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006 Jan 19; 354(3): 251–60
123.
go back to reference Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 Jul 14; 292(2): 191–201PubMedCrossRef Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 Jul 14; 292(2): 191–201PubMedCrossRef
124.
go back to reference Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20(4): 743–6PubMedCrossRef Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20(4): 743–6PubMedCrossRef
125.
go back to reference Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005 Apr 15; 40(8): 1194–8PubMedCrossRef Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005 Apr 15; 40(8): 1194–8PubMedCrossRef
126.
go back to reference Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005 Jan 3; 19(1): 93–5PubMedCrossRef Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005 Jan 3; 19(1): 93–5PubMedCrossRef
127.
go back to reference Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002 Apr; 54(1): 37–45PubMedCrossRef Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002 Apr; 54(1): 37–45PubMedCrossRef
128.
go back to reference Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001 Jul; 32(7): 734–40PubMedCrossRef Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001 Jul; 32(7): 734–40PubMedCrossRef
129.
go back to reference Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999 Oct; 29(4): 948–9PubMedCrossRef Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999 Oct; 29(4): 948–9PubMedCrossRef
130.
go back to reference Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005 Mar 25; 19(5): 455–62PubMedCrossRef Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005 Mar 25; 19(5): 455–62PubMedCrossRef
131.
go back to reference Viread [package insert]. Foster City (CA): Gilead Sciences, 2006 Mar Viread [package insert]. Foster City (CA): Gilead Sciences, 2006 Mar
132.
go back to reference Fine DM, Atta MG. Review: kidney disease in the HIV-infected patient. AIDS Patient Care STDS 2007 Nov; 21(11): 813–24PubMedCrossRef Fine DM, Atta MG. Review: kidney disease in the HIV-infected patient. AIDS Patient Care STDS 2007 Nov; 21(11): 813–24PubMedCrossRef
133.
go back to reference Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993 Mar 11; 328(10): 703–6PubMedCrossRef Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993 Mar 11; 328(10): 703–6PubMedCrossRef
134.
go back to reference Perazella MA. Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high-risk patients. Am J Ther 1997 Sep–Oct; 4(9–10): 343–8PubMedCrossRef Perazella MA. Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high-risk patients. Am J Ther 1997 Sep–Oct; 4(9–10): 343–8PubMedCrossRef
135.
go back to reference Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf 2000 Mar; 22(3): 227–36PubMedCrossRef Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf 2000 Mar; 22(3): 227–36PubMedCrossRef
136.
go back to reference Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995 Jan 15; 122(2): 103–6PubMed Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995 Jan 15; 122(2): 103–6PubMed
137.
go back to reference Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999 Sep; 246(3): 247–52PubMedCrossRef Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999 Sep; 246(3): 247–52PubMedCrossRef
138.
go back to reference Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002 Feb; 49 Suppl. 1: 37–41CrossRef Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002 Feb; 49 Suppl. 1: 37–41CrossRef
139.
go back to reference Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988 Jun; 84(6): 1067–71PubMedCrossRef Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988 Jun; 84(6): 1067–71PubMedCrossRef
140.
go back to reference Blossom AP, Cleary JD, Daley WP. Acyclovir-induced crystalluria [letter]. Ann Pharmacother 2002 Mar; 36(3): 526PubMedCrossRef Blossom AP, Cleary JD, Daley WP. Acyclovir-induced crystalluria [letter]. Ann Pharmacother 2002 Mar; 36(3): 526PubMedCrossRef
141.
go back to reference Smith DE, Hills DA, Harman C, et al. Nebulized pentamidine for the prevention of Pneumocystis carinii pneumonia in AIDS patients: experience of 173 patients and a review of the literature. Q J Med 1991 Jul; 80(291): 619–29PubMed Smith DE, Hills DA, Harman C, et al. Nebulized pentamidine for the prevention of Pneumocystis carinii pneumonia in AIDS patients: experience of 173 patients and a review of the literature. Q J Med 1991 Jul; 80(291): 619–29PubMed
142.
go back to reference Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 1997 Apr; 29(4): 514–25PubMedCrossRef Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 1997 Apr; 29(4): 514–25PubMedCrossRef
143.
go back to reference Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998 Sep 5; 352(9130): 783–4PubMedCrossRef Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998 Sep 5; 352(9130): 783–4PubMedCrossRef
144.
go back to reference Scialla JJ, Atta MG, Fine DM. Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. AIDS 2007 Jan 11; 21(2): 263–4PubMedCrossRef Scialla JJ, Atta MG, Fine DM. Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. AIDS 2007 Jan 11; 21(2): 263–4PubMedCrossRef
145.
go back to reference Ross MJ, Fan C, Ross MD, et al. HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acquir Immune Defic Syndr 2006 May; 42(1): 1–11PubMedCrossRef Ross MJ, Fan C, Ross MD, et al. HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acquir Immune Defic Syndr 2006 May; 42(1): 1–11PubMedCrossRef
146.
go back to reference Briggs WA, Tanawattanacharoen S, Choi MJ, et al. Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 1996 Oct; 28(4): 618–21PubMedCrossRef Briggs WA, Tanawattanacharoen S, Choi MJ, et al. Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 1996 Oct; 28(4): 618–21PubMedCrossRef
147.
go back to reference Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000 Sep; 58(3): 1253–60PubMedCrossRef Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000 Sep; 58(3): 1253–60PubMedCrossRef
148.
go back to reference Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996 Jul; 101(1): 41–8PubMedCrossRef Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996 Jul; 101(1): 41–8PubMedCrossRef
149.
go back to reference Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 1998 Nov; 114(5): 1258–63PubMedCrossRef Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 1998 Nov; 114(5): 1258–63PubMedCrossRef
150.
go back to reference Martos A, Podzamczer D, Martinez-Lacasa J, et al. Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS 1995 Sep; 9(9): 1037–41PubMedCrossRef Martos A, Podzamczer D, Martinez-Lacasa J, et al. Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS 1995 Sep; 9(9): 1037–41PubMedCrossRef
151.
go back to reference Burns GC, Matute R, Onyema D, et al. Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report. Am J Kidney Dis 1994 Mar; 23(3): 441–3PubMed Burns GC, Matute R, Onyema D, et al. Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report. Am J Kidney Dis 1994 Mar; 23(3): 441–3PubMed
152.
go back to reference Burns GC, Paul SK, Toth IR, et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997 Jul; 8(7): 1140–6PubMed Burns GC, Paul SK, Toth IR, et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997 Jul; 8(7): 1140–6PubMed
153.
go back to reference Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996 Aug; 28(2): 202–8PubMedCrossRef Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996 Aug; 28(2): 202–8PubMedCrossRef
154.
go back to reference Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003 Oct; 64(4): 1462–71PubMedCrossRef Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003 Oct; 64(4): 1462–71PubMedCrossRef
155.
go back to reference Ortiz C, Meneses R, Jaffe D, et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988 Aug; 34(2): 248–53PubMedCrossRef Ortiz C, Meneses R, Jaffe D, et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988 Aug; 34(2): 248–53PubMedCrossRef
156.
go back to reference Tebben JA, Rigsby MO, Selwyn PA, et al. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 1993 Jul; 44(1): 191–8PubMedCrossRef Tebben JA, Rigsby MO, Selwyn PA, et al. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 1993 Jul; 44(1): 191–8PubMedCrossRef
157.
go back to reference Abbott KC, Hypolite I, Welch PG, et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001 Sep–Oct; 14(5): 377–83PubMed Abbott KC, Hypolite I, Welch PG, et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001 Sep–Oct; 14(5): 377–83PubMed
158.
go back to reference Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002 Jul; 13(7): 1889–93PubMedCrossRef Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002 Jul; 13(7): 1889–93PubMedCrossRef
159.
go back to reference Macrae J, Friedman AL, Eggers P, et al. Improved survival in HIV-infected African-Americans with ESRD. Clin Nephrol 2005 Aug; 64(2): 124–8PubMed Macrae J, Friedman AL, Eggers P, et al. Improved survival in HIV-infected African-Americans with ESRD. Clin Nephrol 2005 Aug; 64(2): 124–8PubMed
160.
go back to reference Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006 Sep; 3(3): 132–8PubMedCrossRef Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006 Sep; 3(3): 132–8PubMedCrossRef
161.
go back to reference Abbott KC, Swanson SJ, Agodoa LY, et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004 Jun; 15(6): 1633–9PubMedCrossRef Abbott KC, Swanson SJ, Agodoa LY, et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004 Jun; 15(6): 1633–9PubMedCrossRef
162.
go back to reference Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005 Apr; 67(4): 1622–9PubMedCrossRef Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005 Apr; 67(4): 1622–9PubMedCrossRef
163.
go back to reference Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003 Feb 27; 75(4): 425–9PubMedCrossRef Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003 Feb 27; 75(4): 425–9PubMedCrossRef
164.
go back to reference Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007 Sep 15; 84(5): 563–71PubMedCrossRef Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007 Sep 15; 84(5): 563–71PubMedCrossRef
Metadata
Title
Renal Disease in Patients with HIV Infection
Epidemiology, Pathogenesis and Management
Authors
Dr Derek M. Fine
Mark A. Perazella
Gregory M. Lucas
Mohamed G. Atta
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868070-00006

Other articles of this Issue 7/2008

Drugs 7/2008 Go to the issue

Adis Drug Profile

Mosapride